Trial reportInternational journal of radiation oncology, biology, physics2026
Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911.
Trial report in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026Review
- High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option.Journal of contemporary brachytherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeLocoregionally recurrent squamous cell carcinoma of the head and neck and second primary tumors (SPTs) in previously irradiated fields, if not resectable, are virtually always fatal. Chemotherapy alone yields a median survival of 10 to 11 months and 5-year overall survival (OS) rates of <5%. Concurrent reirradiation and chemotherapy constitutes an alternative, nonstandard strategy. Herein, we report the long-term outcomes of NRG Oncology Radiation Therapy Oncology Group 9911, a phase II trial of split-course radiation therapy (RT) and concurrent paclitaxel and cisplatin. METHODS AND MATERIALS: Eligibility stipulated measurable, recurrent squamous cell carcinoma of the head and neck or SPT in previously irradiated fields, performance status 0-1, and adequate end-organ indices. Patients received split course, twice-daily RT (1.5 Gy/fraction twice a day × 5 days every 2 weeks ×4), plus cisplatin (15 mg/m
resultsBetween March 2000 and June 2003, 105 patients were enrolled; 100 patients were analyzable (76% male, median age 60 years). Oropharynx (41%) and oral cavity (27%) were the predominant primary sites. A total of 23% had SPT. Median prior RT dose was 65.7 Gy. Overall, 73% of patients completed all chemotherapy. Nine treatment-related deaths (9%) occurred: 5 in the acute and 4 in the late setting. Survival was significantly improved over historical control (P = .01) with 5-year survival increased from 3.8% (95% CI, 0.0-8.0) to 14.9% (95% CI, 7.9-21.9). Five-year progression-free survival was 7.0% (95% CI, 2.0-12.0). A total of 64.9% died of incident cancer, 3.2% of SPT, and 22.3% of noncancer or unknown causes. In 1-year survivors, the rate of subsequent late grade 4-5 toxicity was significantly higher than historical control (P = .02), with 5-year cumulative incidence of 22.4% (95% CI, 11.8-35.1) compared with 3.2% (95% CI, 0.2-14.5).
conclusionsDespite a high incidence of grade 5 toxicity, OS rates for this trial evaluating concurrent split course twice a day reirradiation with cisplatin and paclitaxel exceeded results seen historically with chemotherapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.